Life Sciences Archive » February, 2016

Life Sciences - February, 2016

333 articles

• Forest Fights Class Claims In Antidepressant Marketing MDL
• IRS Had Right To Adjust Guidant's Income, Court Rules
• Sterlization Device Essure Stays On While Bayer Studies Risks
• Drug Patent Battler Asks: 'What's Michelle Lee Hiding?'
• USPTO Slams Pharma Co.'s High Court Bid To Extend Patents
• Justices Leave Alone 7th Circ. Challenge To Class Standard
• Valeant Pharmaceuticals Faces New Investigation By SEC
• Fla. Nursery Wrongly Passed Over For Marijuana License
• Amgen Patent Suit Targets Sandoz's Enbrel Biosimilar
• Aggrenox Buyers Cry Foul In Pay-For-Delay Discovery Row
• Justices Won't Hear Girardi's $10M Avandia Fee Fight
• Hip Implant Recipient Says $11M Jury Award Was Correct
• Trial Pros: Proskauer's Steve Bauer
• CVS Flu Relief Nothing But A Sugar Pill, Proposed Class Says
• Cross-Agency Collaboration: A New Normal For Product Cos.
• Experts Get Voice In Lilly's $370M Canadian Patent Fight
• Walgreen Booted From Opana MDL But Promises Comeback
• Roxane Looks To Zap Litigation Threat Over Generic Fanapt
• Nu Skin Pays $47M To End Investor Row Over China Ops
• Fed. Circ. Asked To Rethink ITC Data-Blocking Order
• Drug Co. Not Covered For 'Pill Mill' Suit, 7th Circ. Told
• Supplement Maker Fights Class Cert. Revival In False Ad Suit
• FTC Backs Off Some Doc Demands In Androgel Fight
• US, EU Swap Regulatory Cooperation Offers In TTIP
• Reckitt Benckiser Wins Transfer Of NJ Wrongful Firing Suit
• Fish & Richardson Escapes DQ Bid In Cialis Patent Row
• Morgan Lewis Adds 4 K&L Gates IP Partners In Chicago
• Philly Court Urged To Consolidate Testosterone Cases
• Taxation With Representation: Skadden, MoFo, Sidley
• Fed. Circ. Finds Howmedica Polymer Patent Is Invalid
• FTC Sets Conditions For $2.2B Hikma, Boehringer Deal
• Eli Lilly Insurer Says Brazilian Pollution Suits Not Covered
• KaloBios Close To $10M Financing After Drug Rights Buy
• Shkreli Says He Won't Intimidate Witnesses In SEC Case
• Tyco Can't Delay $60M Drug Heist Suit, Judge Rules
• MusclePharm Says Insurer Ignored Policy In Coverage Denial
• 1st Circ. Charts Conservative Post-Actavis Course In Loestrin
• What A Reversal In Stryker And Halo Would Mean
• Merck Gets K-Dur Pay-For-Delay Antitrust Case Narrowed
• Law360 Life Sciences Editorial Advisory Board
• Allstate Says Urine Testing Scheme Conned It Out Of $1.3M
• Hospital's Heart-Disease Test Patents Ruled Invalid Under Alice
• J&J Unit Argues Time Bar On Risperdal Claims Should Stand
• Morgan Stanley Ties Marred $1.3B Affymetrix Deal, Suit Says
• EU Greenlights $5.5B Dental Biz Merger With Tweaks
• Pfizer Said To Save $35B In Taxes With Move To Ireland
• McKesson Drops $1.2B On Oncology Businesses
• J&J Talc Verdict Is Product Liability Game-Changer
• 5 Legal Writing Cliches Sure To Come Back And Bite You
• 5 Tips For Founding A Successful Law Firm
• A Look At FTC's Amicus Brief In Nexium
• Ex-Stiefel Exec Tells 11th Circ. Jury Instructions Fell Short
• US, Cuba Move Closer Together On Cybersecrity Issues
• Weight Loss Supplement Maker Can't Trim FTC Suit
• Costco, Apotex Get Generic Lipitor Labeling Suit Tossed
• Pharma Groups, Economists Knock Effexor Antitrust Appeal
• Kyle Bass' Coalition Gets PTAB Review Of Anacor Patents
• NIH Says Zika Vaccine Could Be Ready For Trials By Summer
• GSK, Teva Ask Justices To Take Lamictal Pay-For-Delay Case
• Silicon Valley Startup Valuations Start To Plateau
• Senate Easily Confirms Califf To Lead FDA
• J&J Unit Looks To Dodge $13.5M Pelvic Mesh Verdict
• ANDA Access Negotiations May Affect Attorney Fee Liability
• 5 Law Office Design Tips Before Moving To Latin America
• Loestrin Ruling Signals Non-Cash Deals Won't Evade Actavis
• Kyle Bass Group Gets PTAB To Eye Pozen Drug Patent
• Shareholders Win Cert. In Suit Over Tibetan Pharma Co.'s IPO
• High Court Appears Set To Relax Patent Damages Test
• FDA Warning Wire: Doc Chided For Lax Clinical Trial Screening
• Holland & Knight Snags IP Pro From Kenyon & Kenyon In NY
• Black Box Warning On Opioid-Benzo Mixing Pushed At FDA
• Trade Judge OKs Hearing In Hemophilia Drug Import Dispute
• KaloBios Seeks Speedy Approval To Buy Chagas Drug Rights
• Stock Tipper Asks 3rd Circ. To Nix SEC Pact After Newman
• Supple Says Judge Can't Sever Injunction Bid In False Ad Suit
• Actavis Says Endo Cites Wrong Precedent In False Ad Suit
• NuVasive Hit With $42M Jury Verdict Over Poaching Claims
• Genelux Founder Asks Del. Justices For Attys' Fees Award
• Valeant Plans To Restate Results In Wake Of Pharmacy Crisis
• HQ Settles Baxter's Dispute Over Arrhythmia Drug Generic
• London's Carpmaels & Ransford Adds 2 IP Pros As Partners
• J&J Slammed With $72M Verdict In Talc Cancer Case
• ResMed Pays $800M For Health Care Software Co. Brightree
• Science Or Advocacy? Expert Challenges And Peer Review
• French Antitrust Enforcement Trends You Should Know About
• Wis. Tribe Pushes Judge To Find Right To Grow Hemp
• Lee & Hayes Adds Life Sciences Partner From K&L Gates
• 1st Circ. Revives Loestrin Pay-For-Delay Suit
• AVX Wants $37.5M Greatbatch Award Axed In Patent Fight
• 9th Circ. Won't Rethink Travelers' Win In KFx Patent Row
• Enzo Can't Revive $61M Jury Win In DNA Patent Row
• Senate Clears Way For Vote On Califf As FDA Chief
• GSK Wants To Know If MDL Plaintiffs Took Generic Zofran
• SEC Speaks '16: Enforcement Agenda Goes Beyond Disclosure
• Duke Asks Fed. Circ. To Revive Claims In Treatment Patent
• Immunotherapy Biotech Syndax Sets Terms On $66M IPO
• Nicoll Davis DQ Sought In Pill Maker's Kickback Row
• Biotech Co. Says Chemist Stole Patents For Own Firm
• Medicines Co. To Pay $4.25M To Settle Stock Drop Suit
• Why Sandoz Appeal To High Court Is Important For Biosimilars
• Congressional Outlook 2016: Patents
• High Court Damages Case Could Give Patent Owners An Edge
• Dacheng Parts With Chinese Pharma Client In $6M Suit
• Dow Can't Trim 8% Interest On $455M Award During Appeal
• Feds Fear Shkreli Will Intimidate Witnesses In SEC Fraud Row
• FTC Orders Hikma To Divest Generics Rights In $5M Deal
• Fed. Circ. Pressed To Nix ITC Data-Blocking Appeal
• AstraZeneca Ducks Row Over Too-Broad Patent
• Fla. Hits Humana With Penalty Over HIV Drugs Pricing
• Florida Trader Cops To $1.2M Insider Trading Haul
• OPINION: Big Law's Perverse Incentive System
• Bard Pushes For Quick End To Hernia Patch Death Suit
• Teva Offers Antitrust Concessions For $40.5B Generics Deal
• Fed. Circ. Says Inequitable Conduct Dooms Prosthetics Patent
• AbbVie, Besins Look To Block Doc Requests In AndroGel Suit
• GSK Ruling Raises Bar For Pharma On Brand Label Warnings
• Reed Smith Reels In Ex-Fish & Richardson IP Partner In NY
• Warner Chilcott Aims To Nix Suits Alleging Generic Blocking
• Gaming Whiz Calls Shkreli An E-Sports Deadbeat In NY Suit
• More Biotech IPOs Likely To Rely On Insiders Amid Slump
• Taxation With Representation: Schulte, Skadden, Kirkland
• Chicago Defends Painkiller Claims Against Drug Cos.
• How The Zika Virus Affects Employment-Related Travel
• Resolved FCPA Enforcement Actions Drop To 10-Year Low
• Insurer Loses Bid To Avoid Tainted Heparin Defense Coverage
• Cooley Brings Back Life Sciences Pro From Hogan Lovells
• Ga. Jury Hits J&J Unit With $4.4M Verdict Over Pelvic Implant
• Chancery OKs Shareholder Deal On $5.2B NPS-Shire Sale
• SEC Takes Shot At Kaye Scholer Atty In Shkreli Civil Case
• NuVasive Didn't Infringe Medtronic Patent, Judge Says
• 3rd Circ. Agrees Doc's Words Doom Suit Over GSK's Avandia
• Real Estate Rumors: Google, Invesco, Panattoni Development
• Hyland's Halts Theory Swap In Snake Oil Suit
• 3-D Bioprinting: 5 Things Medical Device Cos. Should Know
• TriReme Asks Fed. Circ. To Nix $20M Catheter IP Suit
• Arch Wants Eli Lilly's Contamination Coverage Suit Tossed
• Shkreli's Ex-Co. OK To Pay $198K In Bonuses, Judge Says
• Fresenius Strikes $250M Deal To Settle Dialysis Drug MDL
• Patients Say Genzyme Mischaracterizes Diluted-Drug Claims
• Businesses, Profs Want Voice In Lilly's Canadian Patent Fight
• Sex-Selection Patents Upheld In $6M Jury Verdict
• Pa. High Court OKs State Farm's Med Payment Formula
• NY Orthotics Startup Discriminated Against Exec, Suit Says
• 3rd Circ. Asked To Revive Allergan Product-Hopping Suit
• Eli Lilly, Liberty Mutual Settle Contamination Coverage Suit
• Congressional Outlook 2016: Health Care
• Sandoz Seeks High Court Take On Biosimilar Law
• PTAB Pops Dr. Reddy's Bid For Reviews Of Acne Med Patent
• Wyeth, Teva Say Effexor Pay-For-Delay Suit Fell Short
• Battling Revenue Doom And Gloom With Litigation Finance
• Amgen Fights Dismissal Bid In Del. Biosimilar Drug Case
• Cherokee Nation Wants Risperdal Suit Back In State Court
• Shkreli's Ex-Drug Co. Hasn't Justified Bonuses, Judge Says
• FDA Warning Wire: Quality Of Popular Pet Products In Doubt
• Film, Music Lobbies Say ITC Can Police Online Infringement
• Whistleblower Urges 11th Circ. To Revive Fresenius FCA Row
• Nexium Ruling Could Hurt Antitrust Cases, FTC Tells 1st Circ.
• Stryker Pays $1.28B For Medical Device Maker Physio-Control
• Pfizer To Pay $785M To Settle FCA Claims Over Protonix
• The Legacy Of Justice Scalia On IP Law
• Scalia's Rapid-Fire Questioning Transformed Oral Arguments
• Justice Scalia Leaves His Mark In Biting, Clever Dissents
• Death Of Scalia Leaves High Court Docket In Limbo
• Scalia Leaves Mighty Legacy At High Court
• GOP Attys Would Likely Back Srinivasan To Replace Scalia
• Scalia's Originalism Shifted The Constitutional Debate
• Scalia Took On Gun Control, Class Actions In Top Opinions
• Supreme Court Justice Antonin Scalia Dies At 79
• USPTO Tells Fed. Circ. Ethicon's Stent IP Claims Are Invalid
• FDA Rebuffs Allergan On Generic Restasis Tests
• DFB Pharma Wants S&N To Cough Up $26.7M In Dispute
• Nobel Tells 9th Circ. To Nix $2.3M Fee Award In Implant Deal
• Apotex, Lupin Settle Paxil Infringement Fight
• GSK Shakes Diabetes Drug Row At 3rd Circ.
• CVS To Pay $8M To Settle Oxycodone Sales Row With Feds
• Deals Rumor Mill: Intercept Pharma, Barclays, Banco Poplare
• Additional Thoughts On Class Plaintiff 'Pick-Offs'
• Shkreli, Kaye Scholer Atty Say SEC Case Can't Wait
• BioScrip To Pay Shareholders $11M In Exjade Fallout
• GSK Fined $54M Over UK 'Pay-For-Delay' Deals
• Amended Rule 26's Proportionality Standard: The First 60 Days
• GSK Gets Quick No To Request To Duck Reed Smith Case
• Merck Investors Win Prelim OK Of $1B Vioxx Marketing Deal
• Sen. Murkowski Lifts 'Frankenfish' Hold On FDA Chief Nominee
• Siblings Slam Bard's Bid To Escape Hernia Patch Death Suit
• Express Scripts Counters Bid To Transfer Antitrust Suit
• Shire, Adderall Buyers Agree To Settle Pay-For-Delay Case
• ACA, Zika, Opioids Hot Topics In HHS Budget
• Philly Pelvic Mesh Verdicts Spell Trouble For J&J
• Howmedica Staves Off Suit Over Toxic Spinal Implant
• Biotechs Stumble Following $145M In Pricings
• Pharma PTAB Petitions Jump As Firms Test New Forum
• Rx. Co. Sues Law Firm For Losing Case Against Ex-Workers
• Drug Advertising On Social Media: US Vs. Canada
• FaegreBD Adds 2 Litigators To LA Office
• Endo Can't Dump $112M Painkiller Pay-For-Delay Suit
• 3rd Circ. Ruling Backs RICO Claims Against Glaxo, Court Told
• Bankrupt KaloBios Faces Fire For Employee Bonus Plan
• NJ Shareholder Suit Over Nymox's Prostate Drug Trials Tossed
• Cravath Reps Mylan In $9.9B Deal For Swedish Drugmaker
• Steptoe Adds IP Partner From Ropes & Gray
• Smartphone, Pharma Giants Dominate List Of Top IP Targets
• Hikma Chops $2.7B Boehringer Generics Offer By 20%
• Mylan Pushes 3rd Circ. To Revive Doryx Product-Hopping Suit
• PE-Backed US Foods Leads Trio Of New IPO Filings
• FDA Warning Can't Bar Fresenius Dialysis Suits, Court Told
• Investing In The Marijuana Industry: Where We Stand
• How Does Skadden Stay No. 1?
• J&J Hit With $13.5M Verdict In 2nd Philly Pelvic Mesh Trial
• Corin Hip Implant Defect Suit Nixed For Lack Of Evidence
• FDA Seeks $5.1B Budget, Including Funds For Food Safety
• Hagens Berman Loses Sanctions Appeal In Thalidomide Row
• FDA Warning Wire: Cannabis Therapy, Cattle Feed, Frozen Fish
• FDA Panel OKs Celltrion Biosimilar Of Janssen's Remicade
• Bid For Info On Suboxone Resales Is Premature, Judge Says
• Jury Ready To Decide 2nd Philly Pelvic Mesh Case
• Biotechs Pull Offerings Totaling $155M Amid Weak Markets
• 7 Bills Promoting Medical Innovation Pass Senate Committee
• Costco Slams Generic Lipitor Labeling Suit
• OPINION: The Road To Partnership Must Keep Evolving
• Shkreli Hit With Copyright Suit Over Wu-Tang Album Art
• MusclePharm Says Liberty Unquestionably Owes For SEC Probe
• Fanelli Haag Adds IP Partner From Kenyon & Kenyon
• How Pharma Cos. Can Lessen The Risk Of Gov't Action
• Kaye Scholer Atty Taps Gupta Prosecutor In Shkreli Case
• PTAB's Ax Of Stanford DNA Test Patent Backed By Fed. Circ.
• J&J Can't Slip Baby Lotion False Ad Class Action
• Don't Limit Aggrenox Pay For Delay Discovery, Judge Told
• Chancery Nixes Injunction in Feud Over Akrimax Drug Rights
• Nexium Buyers Push 1st Circ. For New Pay-For-Delay Trial
• Chamber, CEOs Back P&G In Class Cert. Protest At High Court
• FDA Tackles Opioids Amid Rare Political Pressure
• Philly Cipro, Avelox, Levaquin Cases Won't Be Consolidated
• White House Wants $1.8B To Fight Zika Virus
• Homeopathy False Ad Beef Should Stick To NY, Hyland's Says
• NJ Jury Dings Supplement Maker $1M In Contract Row
• Has Gene By Gene Unzipped TCPA Insurance Exclusions?
• GCs Name Best Of The Best Attorneys
• 8 Firms Boast The Most Client-Savvy Attorneys
• Supernus Gets Partial Win In Drug Patent Row With Actavis
• FTC Wants Patent Prosecution Docs In Androgel Fight
• Amgen Urges No Exceptions To Biosimilar Notice At Fed. Circ.
• Fed. Circ. Revives TriReme Catheter Patent Inventor Row
• 3rd Circ. Says No Rehearing Or Fees In Thalidomide Suit
• 4 Firms Set To Guide Billion-Dollar Slate Of IPOs
• PE-Backed Therapure Biopharma Delays $93M Canadian IPO
• 2nd Circ. Urged To Revive Actos Pay For Delay Row
• McDermott Taps BioTech Markets Pro For NY Office
• Fed. Circ. Affirms Validity Of Vascular Stent Patent
• ScriptPro Asks Fed. Circ. To Save Pill-Dispenser Patent
• Taxation With Representation: Kirkland, Sullivan, Norton
• 6th Circ. Told Pliva Can't Dodge FDA's Stance On Warnings
• Proportionality Ruling Raises Concerns About Rule 26 Change
• FDA Staff Back Celltrion's Remicade Biosimilar
• Astellas To Pay $13.3M To Settle Prograf Antitrust Case
• Judge In Reed Smith Suicide Case Can't Beeline To Trial: GSK
• Diet Pill Maker Can't Skirt Campbell-Ewald With Deposit
• AbbVie, Others Escape Some Testosterone Therapy Claims
• Medicare's Biosimilar Pay Policy Draws Congressional Fire
• FDA Announces Review Of Opioid Policies
• Liberty Says MusclePharm's $3M Indemnity Suit Won't Fly
• KaloBios Can Keep Control Of Bankruptcy
• Anda Pushes For W.Va. 'Pill Mill' Coverage In 11th Circ.
• Judge Takes 2nd Look At $174M 'Short And Distort' Damages
• Deals Rumor Mill: Mattel, Sharp, Ardian
• Health Care Deal Trends Emerge From JP Morgan 2016
• Clyde & Co. Snags Fasken Martineau's IP Litigation Head
• Bayer Making Progress Settling $175M R&D Tax Row With IRS
• Stanford Says Its DNA Patent Is 'Antithesis' Of Prior Art
• KemPharm Prices $75M Private Bond After Nixing Follow-On
• IRS Deduction Denial Beyond Jurisdiction, Pot Dispensary Says
• FDA's Strategy For Interoperable Medical Device Regulation
• Reps. Attack Drug Price Hikes As Silent Shkreli Tweets Insults
• Bard Mesh Patients Cite Slow MDL Pace In Bid To Move Suits
• Bayer Urges 2nd Circ. To Uphold Dismissal Of Mirena Claims
• Biogen Escapes 1 Of 4 FCA Suits Over Alleged Kickbacks
• Taylor-Wharton Wants Breathing Room For Ch. 11 Plan
• 7th Circ. Rules Out Skin-Disease Claims Against Drugmaker
• Sens. Push Pay-For-Delay Ban To Slow Drug Spending
• KaloBios Fights Trustee As Shkreli's DC Showdown Nears
• GNC, Arthritis Drug Makers Escape False Ad Suit, For Now
• Biotechs End 2016 IPO Drought With $252.8M Total Pricing
• Shkreli, Retrophin Strike $3M Deal To End Investor Suit
• 'Bogus' Diet Pill Co. Pays $43M To Settle FTC False Ad Claims
• Unexpected Uncertainty For The 340B Drug Pricing Program
• Brafman Makes Pharma Bad Boy Shkreli Take Vow of Silence
• As Signing Nears, Froman Offers Glimpse Of TPP Strategy
• Generic Co. Loses Another Round At PTAB In Zomig IP Fight
• Genentech Misstates Breast Cancer Drug Amount, Suit Says
• J&J Escapes FCA Row Over Allegedly Faulty Hip Implants
• Fresenius Wants Over 300 Cases Out Of Dialysis Drug MDL
• Endo, Lidoderm Buyers Clash Over Docs In Pay-For-Delay Suit
• FDA Warning Wire: Ipca, Dog Thyroid Pills, Compounder Attire
• Dr. Oz Sued Over 'Miracle' Fat-Burning Supplement Promotion
• CardioNet Wins $1M In Fees After MedTel Found In Contempt
• Lawmaker Details Price Hike Strategies At Turing, Valeant
• ICC Rejects Claims That Enzymotec's IPO Breached Deal
• House Falls Short On Veto Override For ACA Repeal Bill
• Cephalon Trims 1 Year Of Provigil Claims In FCA Suit
• Boston Scientific, Bard Beat $28M Pelvic Mesh Defect Suit
• Deals Rumor Mill: ChemChina, Roche Holding, Barracuda
• Shkreli Taps Celeb Defense Atty In Securities Fraud Fight
• UK Cancer Drug Developer Raises $86M In Funding Round
• Watson Labs Says Merck Contraceptive Patent Nixed By Sale
• Gilead Can't Invalidate Merck's Drug Patents In IP Fight
• Stryker Wins Sanctions After Ex-Employee Hides Evidence
• Shire Says Expert Should Speak In Adderall Antitrust Suit
• PTAB Rightly Axed Electrosurgery Patents, Fed Circ. Told
• Index Ventures Forms New Life Sciences Investment Firm
• Hagens Berman Tells 3rd Circ. Facts Are Disputed In GSK Suit
• TE Pays $895M For Permira-Backed Medical Device Maker
• Medical Device Cybersecurity: What Pharma Cos. Should Know
• CVS Hits Endo With Pay-For-Delay Suit Over Painkiller Opana
• J&J Fights Cherokee Bid To Move Risperdal Lawsuit
• Namenda Buyers Say Product Hopping Class Action Has Legs
• US Wants Trustee Or Ch. 7 For KaloBios After Shkreli Arrest
• BigLaw Brother Didn't Bias Arbitrator, 9th Circ. Told
• Boston Scientific, Bard Pelvic Mesh Case Goes To Jury
• Consumer Seeks Win In Generic Lipitor Labeling Suit
• Fed. Circ. Affirms Ruling Axing 4 Purdue OxyContin Patents
• K&L Gates Snags High-Stakes Litigator From Latham
• Egg Donors Get Pay Limits Axed With Antitrust Settlement
• Zika Virus Is Global Emergency, WHO Declares
• CVS Hit With Suit Over Misleading Dietary Supplement Label
• Dechert Adds Ex-Norton Rose Antitrust Pro To Paris Office
• Deals Rumor Mill: Sharp, Lavazza, Blackstone Group
• Fed. Circ. Told Atelvia Skepticism Shows Patent Isn't Obvious
• Kirkland & Ellis Reps Abbott In $5.8B Acquisition Of Alere
• Biotechs, Waste Biz Give IPO Pipeline A $585M Rev-Up
• High Court Again Urged To Review Part Of Arthrex IP Loss
• Whistleblower Nets $12.2M Payday In Accredo Kickback Suit
• What The Court Got Wrong About Hatch-Waxman In Alcon
• A Cautionary Tale About 'Other Acts' And Insider Trading